会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • TACKIFIER COMPOUNDS AND METHODS OF USING THE SAME
    • 封装化合物及其使用方法
    • WO2014062625A1
    • 2014-04-24
    • PCT/US2013/064960
    • 2013-10-15
    • IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC.
    • CHEN, Jason Shih-HaoKESSLER, Michael RichardZENNER, Michael Dennis
    • C07D493/04C09J4/00C08F18/00
    • C08F122/20C07D493/04C08G18/3218C08G18/771C08L75/08C08L2201/50C09J4/00C09J135/02
    • The present invention relates to tackifier compounds and methods of using the same. In various embodiments, the present invention provides a tackifier compound including independently substituted or unsubstituted fused rings A and B each independently chosen from (C 5 -C 10 )cycloalkyl and (C 2 -C 10 )heterocyclyl. Fused ring A is substituted with (R 1 ) 1-8 and fused ring B is substituted with -(OC(O)R'C(O)R 2 ) 1-8 . At each occurrence R' is independently chosen from (C 2 -C 10 )alkanylene, (C 2 -C 10 )alkenylene, (C 2 -C 10 )alkynylene, C 5 -C 20 (arylene), and (C 1 -C 20 )heteroarylene, wherein R' is unsubstituted or substituted. At each occurrence R 1 is independently selected from -OH, -OR 3 , and -OC(O)R'C(O)R 2 . At each occurrence R 2 is independently chosen from -OH, -OR 3 , -NH 2 , -NHR 3 , and -NR 3 2 . At each occurrence R 3 is independently chosen from (C 1 -C 10 )alkanyl, (C 2 -C 10 )alkenyl, (C 2 -C 10 )alkynyl, C 5 -C 20 (aryl), and (C 1 -C 20 )heteroaryl, wherein R 3 is unsubstituted or substituted.
    • 本发明涉及增粘剂化合物及其使用方法。 在各种实施方案中,本发明提供包含各自独立地取代或未取代的稠合环A和B的增粘剂化合物,各自独立地选自(C 5 -C 10)环烷基和(C 2 -C 10)杂环基。 稠环A被(R 1)1-8取代,稠环B被 - (OC(O)R'C(O)R 2)1-8取代。 在每次出现时,R'独立地选自(C 2 -C 10)亚烷基,(C 2 -C 10)亚烯基,(C 2 -C 10)亚炔基,C 5 -C 20(亚芳基)和(C 1 -C 20)亚杂芳基,其中R' 或取代。 在每次出现时,R 1独立地选自-OH,-OR 3和-OC(O)R'C(O)R 2。 在每次出现时,R2独立地选自-OH,-OR3,-NH2,-NHR3和-NR3 2.在每次出现时,R3独立地选自(C1-C10)烷基,(C2-C10)烯基,(C2- C10)炔基,C5-C20(芳基)和(C1-C20)杂芳基,其中R3是未取代或取代的。
    • 6. 发明申请
    • WOUND HEALING POLYMERIC NETWORKS
    • 创伤治疗聚合物网络
    • WO2007005792A8
    • 2008-03-27
    • PCT/US2006025915
    • 2006-07-01
    • UNIV PITTSBURGH
    • BECKMAN ERIC JBADYLAK STEPHEN FWELLS ALAN HZHANG JIANYINGFREYTES DONALD
    • A61L26/00A61L15/26A61L15/44
    • C08G18/3821A61K31/28A61K38/39A61K45/06A61K47/59A61K47/60A61L26/0019A61L26/0066A61L26/008A61L2300/104A61L2300/214A61L2300/252A61L2300/402A61L2300/404A61L2300/414A61L2300/418C08G18/10C08G18/3206C08G18/3218C08G18/4833C08G18/771C08G18/8022C08G2230/00
    • A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably biocompatible. The polymerizing molecule can, for example, be dihydroxyphenyl-L-alanine (DOPA) or tyrosine. The composition can also include a second component synthesized by reacting at least one core molecule having a plurality of reactive hydrogen groups with at least one multi-isocyanate functional molecule to create a conjugate including terminal isocyanate groups. The conjugate molecule is reacted with a second polymerizing molecule that is adapted to undergo a free radical polymerization. The second polymerizing molecule includes a reactive hydrogen to react with the isocyanate groups of the conjugate. The second polymerizing molecule retains the ability to undergo the free radical polymerization after reaction with the conjugate. In several embodiments, the first polymerizing molecule and the second polymerizing molecule are the same and dihydroxyphenyl-L-alanine (DOPA) or tyrosine.
    • 组合物包含共价连接到适于进行自由基聚合的第一聚合分子的至少一种生物活性剂。 第一聚合分子保留在生物活性剂附着后进行自由基聚合的能力。 第一聚合分子优选是生物相容的。 聚合分子可以是例如二羟基苯基-L-丙氨酸(DOPA)或酪氨酸。 组合物还可以包括通过使具有多个反应性氢基团的至少一个核心分子与至少一个多异氰酸酯官能分子反应以产生包含末端异氰酸酯基团的缀合物而合成的第二组分。 共轭分子与适于进行自由基聚合的第二聚合分子反应。 第二聚合分子包括与偶联物的异氰酸酯基反应的反应性氢。 第二聚合分子保留在与缀合物反应后进行自由基聚合的能力。 在几个实施方案中,第一聚合分子和第二聚合分子是相同的,并且是二羟基苯基-L-丙氨酸(DOPA)或酪氨酸。